Related references
Note: Only part of the references are listed.Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications
Bao Sun et al.
CARDIOVASCULAR DIABETOLOGY (2021)
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
Aika Miya et al.
JOURNAL OF DIABETES INVESTIGATION (2021)
Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials
Mitsuhisa Komatsu et al.
JOURNAL OF DIABETES INVESTIGATION (2021)
Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes
Lalantha Leelarathna et al.
DIABETES CARE (2020)
Updated Software for Automated Assessment of Glucose Variability and Quality of Glycemic Control in Diabetes
Vanessa Moscardo et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2020)
Comparison of the FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) System and Point-of-Care Capillary Glucose Testing in Hospitalized Patients With Type 2 Diabetes Treated With Basal-Bolus Insulin Regimen
Rodolfo J. Galindo et al.
DIABETES CARE (2020)
Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Raffaella Gentilella et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2019)
Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients With Diabetes With Acute Coronary Syndrome
Edouard Gerbaud et al.
DIABETES CARE (2019)
Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study
Rimei Nishimura et al.
BMJ OPEN (2019)
Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features
Katherine A. Lyseng-Williamson
CLINICAL DRUG INVESTIGATION (2019)
Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development
Bo Ahren
JOURNAL OF DIABETES INVESTIGATION (2019)
Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial
Hirotaka Watada et al.
DIABETES OBESITY & METABOLISM (2019)
Defining High Glycemic Variability in Type 1 Diabetes: Comparison of Multiple Indexes to Identify Patients at Risk of Hypoglycemia
Ana Maria Gomez et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2019)
Glycemic Variability Percentage: A Novel Method for Assessing Glycemic Variability from Continuous Glucose Monitor Data
Thomas A. Peyser et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2018)
Clinical inertia in basal insulin-treated patients with type 2 diabetes - Results from a retrospective database study in Japan (JDDM 43)
Jo Satoh et al.
PLOS ONE (2018)
Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Stephanie A. Amiel et al.
DIABETES CARE (2017)
A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin
Hiroshi Nomoto et al.
DIABETOLOGY & METABOLIC SYNDROME (2017)
Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients
Dieter Ayers et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials
D. Russell-Jones et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2015)
Glucose variability is associated with intensive care unit mortality
Jeroen Hermanides et al.
CRITICAL CARE MEDICINE (2010)
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley et al.
LANCET (2010)
The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
Denise E. Bonds et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
Y. Seino et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes -: Importance of postprandial glycemia to achieve target HbA1c levels
Hans J. Woerle et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Evaluation of a new measure of blood glucose variability in diabetes
Boris P. Kovatchev et al.
DIABETES CARE (2006)
Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies
EB Levitan et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Share Paper
